These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Weight gain due to long term antipsychotic treatment of persistent mental disorders. Tadger S; Melamed Y Psychiatr Danub; 2008 Mar; 20(1):37-41. PubMed ID: 18376329 [TBL] [Abstract][Full Text] [Related]
23. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179 [TBL] [Abstract][Full Text] [Related]
25. Olanzapine pamoate - blockbuster or damp squib? Taylor DM Int J Clin Pract; 2009 Apr; 63(4):540-1. PubMed ID: 19335703 [No Abstract] [Full Text] [Related]
26. [Mortality and cumulative exposure to antipsychotics, antidepressants and benzodiazepines in patients with schizophrenia: an observational follow-up study]. Tiihonenl J; Mittendorfer-Rutz E; Torniainen M; Alexanderson K; Tanskanen A Duodecim; 2016; 132(2):181. PubMed ID: 26939492 [No Abstract] [Full Text] [Related]
27. Antipsychotic-induced weight gain: a review of the literature. Allison DB; Casey DE J Clin Psychiatry; 2001; 62 Suppl 7():22-31. PubMed ID: 11346192 [TBL] [Abstract][Full Text] [Related]
28. Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis. Block JJ Am J Psychiatry; 2006 Oct; 163(10):1838; author reply 1838. PubMed ID: 17012701 [No Abstract] [Full Text] [Related]
29. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study. Novick D; Haro JM; Suarez D; Marques-Teixeira J; Naber D Int Clin Psychopharmacol; 2008 Jul; 23(4):203-8. PubMed ID: 18545058 [TBL] [Abstract][Full Text] [Related]
30. Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns. McClellan JM Am J Psychiatry; 2007 Oct; 164(10):1462-4. PubMed ID: 17898331 [No Abstract] [Full Text] [Related]
32. Olanzapine vs haloperidol for treatment of schizophrenia. Amin M; Shukla VS JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996767 [No Abstract] [Full Text] [Related]
33. Olanzapine vs haloperidol for treatment of schizophrenia. Glazer WM JAMA; 2004 Mar; 291(9):1064-5; author reply 1065-6. PubMed ID: 14996766 [No Abstract] [Full Text] [Related]
34. Methodological concerns in a trial of ziprasidone and olanzapine. Ross DE Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735 [No Abstract] [Full Text] [Related]
35. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Strassnig M; Miewald J; Keshavan M; Ganguli R Schizophr Res; 2007 Jul; 93(1-3):90-8. PubMed ID: 17478082 [TBL] [Abstract][Full Text] [Related]
37. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423 [TBL] [Abstract][Full Text] [Related]
38. Methodological concerns in a trial of ziprasidone and olanzapine. Carnahan RM; Perry PJ Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736 [No Abstract] [Full Text] [Related]
39. Olanzapine for schizophrenia. Med Lett Drugs Ther; 1997 Jan; 39(992):5-6. PubMed ID: 9008682 [No Abstract] [Full Text] [Related]
40. Review of atypical antipsychotics and weight gain. Sussman N J Clin Psychiatry; 2001; 62 Suppl 23():5-12. PubMed ID: 11603886 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]